Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: stoketherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $24.00 | Buy | Chardan Capital Markets |
| 10/14/2024 | $18.00 | Outperform | Leerink Partners |
| 3/26/2024 | Market Perform → Outperform | TD Cowen | |
| 11/20/2023 | Neutral | JP Morgan | |
| 7/25/2023 | Outperform → Market Perform | TD Cowen | |
| 5/1/2023 | $9.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 4/26/2023 | $24.00 | Buy | Canaccord Genuity |
| 1/6/2023 | $22.00 → $9.00 | Buy → Underperform | BofA Securities |
| 10/24/2022 | $30.00 | Mkt Perform → Outperform | SVB Leerink |
| 1/31/2022 | $50.00 | Buy | Jefferies |
Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00
Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00
TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform
JP Morgan resumed coverage of Stoke Therapeutics with a rating of Neutral
TD Cowen downgraded Stoke Therapeutics from Outperform to Market Perform
BofA Securities upgraded Stoke Therapeutics from Underperform to Neutral and set a new price target of $12.00 from $9.00 previously
Canaccord Genuity resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00
BofA Securities downgraded Stoke Therapeutics from Buy to Underperform and set a new price target of $9.00 from $22.00 previously
SVB Leerink upgraded Stoke Therapeutics from Mkt Perform to Outperform and set a new price target of $30.00
Jefferies initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $50.00
SCHEDULE 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
144 - Stoke Therapeutics, Inc. (0001623526) (Subject)
DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)
DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)
S-8 - Stoke Therapeutics, Inc. (0001623526) (Filer)
10-K - Stoke Therapeutics, Inc. (0001623526) (Filer)